Objectives The US National Viral Hepatitis Action Plan calls for major efforts to expand hepatitis C virus (HCV) diagnosis and treatment; prenatal care settings are potential venues for expanding HCV testing. We aimed to characterize the HCV diagnostic cascade for women and infants and investigate factors associated with linkage and follow-up.
multidisciplinary program that cares for pregnant women with substance use disorders. The clinic provides on-site support from psychiatry, social work, nursing, and lactation in conjunction with obstetric providers who specialize in treating women in various stages of recovery and prescribing medications for opioid use disorder.
Data Collection
The RESPECT program data registry includes demographic characteristics, medical history, and pregnancy and birth outcomes abstracted from chart review of women enrolled in RESPECT. Maternal substance use is determined by third trimester reported tobacco use and urine toxicology screens compared with chart evidence of prescribed opioids and opioid agonists at delivery. Zip codes are geocoded into distance from medical center to home zip code geometric center and dichotomized to within or outside the subway system. The EHR was retrospectively queried to add HCV-related laboratory results (HCV antibody [anti-HCV], nucleic acid [RNA] tests, and genotypes, and HIV and hepatitis B virus testing).
Patients
We included all women with a diagnosis of opioid use disorder who delivered a live birth at BMC between January 1, 2006, and December 31, 2015. For the HCV cascade and the multivariable analysis, we included only the most recent pregnancy to not double count women, and only infants at least 18 months old at study end to allow adequate follow-up time for infant HCV screening. Given very few transmission events, our subanalysis of factors associated with vertical transmission of HCV includes all infants regardless of birth order or age at study end.
HCV Cascade of Care Outcomes
The primary outcome was follow-up along the HCV care cascade. We defined key points as follows.
The proportion of women assessed for HCV infection by documented history of HCV diagnosis in the EHR problem list, prior positive anti-HCV, or testing for anti-HCV or HCV RNA during pregnancy (40 weeks before delivery date up to 4 days postpartum); of those assessed for HCV, the proportion with reactive anti-HCV (seropositive) by documented history or result in EHR; of seropositive women, the proportion with HCV RNA testing during pregnancy; the proportion with positive HCV RNA testing during pregnancy (viremic); and of viremic women, the proportion who were linked to HCV care.
We defined linkage to HCV care as documentation of HCV genotype in the EHR during pregnancy through study end. We chose genotype as our proxy for linkage because genotype is a consistent marker for the initiation of further diagnostic evaluation for HCV. 8 To delineate the infant cascade, we used the American Academy of Pediatrics Redbook guidelines, which recommend HCV testing for all infants born to HCV-seropositive mothers, regardless of maternal HCV RNA status (consistent with other published guidelines). [9] [10] [11] [12] We define infant diagnostic cascade outcomes as follows. The proportion born to HCVseropositive mothers with at least 1 anti-HCV or RNA test result in the EHR (but not necessarily complete, appropriate testing for perinatal HCV); the proportion with complete followup, defined as meeting 1 of 4 conditions: (1) confirmed diagnosis of HCV infection by two positive HCV RNA tests at least 1 month apart, (2) confirmed diagnosis of HCV by reactive anti-HCV at age 18 months or greater, or (3) confirmed exclusion of HCV infection by 2 negative HCV RNA tests at least 1 month apart, or (4) by negative anti-HCV at any age; of infants with complete follow-up, proportion diagnosed as HCV-infected; and among infants with HCV infection, proportion linked to HCV care, determined by manual chart review confirmation of visits for chronic HCV followup at BMC. Institutional practice was to schedule all infants for HCV follow-up with pediatric infectious diseases at BMC; however, infants may ultimately have completed screening at alternate locations. A dedicated pediatric infectious diseases nurse at BMC routinely makes multiple attempts to reschedule infants with missed appointments and documents relevant communications with non-BMC providers who may screen infants for HCV. We compared follow-up rates between infants with and without primary care at BMC to account for infants expected to have laboratory data accessible through the EHR. We also completed a chart review of a random subset of 50 infants without complete HCV screening at BMC to categorize whether those infants were truly unscreened. We reviewed charts for notes documenting confirmed HCV testing performed outside the EHR (confirmed screening), notes indicating outside provider intention to screen (likely screening), 2 or more missed appointments for HCV screening without later re-engagement in care (loss to follow-up), or confirmed primary care at BMC without HCV testing completed through study end (confirmed unscreened). For infants in the latter categories, their mothers' records were also checked for evidence of falsepositive HCV testing during pregnancy.
We used a survival analysis to display time until clearance of maternal anti-HCV for infants ultimately screening negative for HCV to inform whether earlier testing schedules might be possible. Given several month gaps between repeat anti-HCV testing in clinical practice, we calculated for each infant the midpoint between the last positive and the first negative anti-HCV as an estimate of predicted time of anti-HCV clearance.
Statistical Analyses
We compared the demographic characteristics and comorbidities in HCV seropositive women with seronegative women using t tests for continuous and c 2 test for categorical variables. Using multivariable logistic regression, we modeled HCV viremic mothers' odds of linking to HCV care adjusting for confounders including maternal age, race, distance from medical center, HIV status, psychiatric diagnoses, tobacco and unprescribed drug use (opioids, benzodiazepines, cocaine, amphetamines, or barbiturates), and opioid agonist therapy at delivery.
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We next modeled predictors of infant diagnostic completion using maternal demographic characteristics, comorbidities, and maternal HCV viremia. Multivariable regression used factors predicting complete follow-up in univariate analysis with an effect size of at least 30%. Finally, we described characteristics of HCV-infected infants.
All data analysis was performed using SAS version 9.4 (SAS Institute, Inc, Cary, North Carolina). Institutional Review Board Approval was obtained from BMC.
Results
Of 879 women with opioid use disorder included in the analysis, 744 (85%) were assessed for HCV infection by review of known HCV infection in the problem list or laboratory testing, and 510 (68% of those assessed) were anti-HCV positive (Figure 1) . Compared with those without HCV, seropositive women were more likely to be white non-Hispanic (P < .001) and have comorbid HIV infection (P = .006) and tobacco use during pregnancy (P < .001; Table I ). Seropositive women were also more likely to be prescribed opioid agonist therapy at delivery (P < .001), but had similar rates of illicit or unprescribed drug use during pregnancy (39% vs 36%; P = .35). All women were hepatitis B surface antigen negative (data not shown); the number of prenatal visits was the same for both groups.
HCV Care Cascade
Of the 510 HCV-seropositive women, 369 (72%) had HCV RNA testing completed during pregnancy (Figure 1) , of whom 261 (71%) had detectable HCV RNA, corresponding with a chronic HCV prevalence estimate among women with opioid disorder at this clinic of at least 30% (261 of 879). Of the 261 viremic mothers, 107 (41%) were linked to HCV care at BMC after pregnancy. If we assume that 68% of untested women were seropositive as well and assume that 71% of these women and of seropositive women without RNA testing were viremic, Among 404 infants included in the cascade (those born to HCV-seropositive mothers and at least 18 months of age at study end), 273 (68%) had evidence of at least 1 HCV laboratory result, but only 180 (45%) had complete evaluation for perinatal HCV acquisition (Figure 1) . Among the 180 screened, 5 transmission events occurred (2.8%), and all 5 infants were linked to care with pediatric infectious diseases specialists for follow-up of chronic HCV. Of 163 infants with initial positive anti-HCV testing followed by a later negative anti-HCV, 50 (31%) were seronegative by 12 months of age and none had positive anti-HCV later than 14 months of age (Figure 2 ; available at www.jpeds.com). Estimating for each infant average age between last positive and first negative anti-HCV, 70% of infants had a predicted negative anti-HCV by 12 months of age, 85% by 15 months, and 99% by 18 months.
In assessing infant follow-up care, we found that 234 of 404 infants (58%) had at least 1 completed visit with pediatric infectious diseases specialists at BMC. Of those, 169 of the 234 (72%) completed diagnostic testing for HCV. Furthermore, of 120 infants (30%) who received primary care at BMC, 97 of the 120 (81%) had complete HCV screening (data not shown).
A chart review of 50 infants without complete HCV screening at BMC demonstrated that 6 (12%) definitely and 12 (24%) likely completed screening elsewhere given documented communication about HCV follow-up with their primary care pediatrician. Five infants (10%) were confirmed unscreened despite primary care at BMC and 23 (46%) seemed to be lost to follow-up given missed appointments for screening. One infant died and 3 had mothers later proven HCV seronegative (false-positive screening during pregnancy). Extrapolating to all 224 infants without complete follow-up, if 56% (125 of 224) were truly unscreened, this predicts a more conservative estimate of 125 of 404 exposed infants (31%) lost to followup and 69% screened (data not shown). In multivariable logistic regression, maternal HIV coinfection was associated with an increased odds of infant HCV diagnostic follow-up completion (aOR, 9.0; 95% CI, 1.1-72.8; Table III ). Maternal methadone maintenance therapy compared with buprenorphine at delivery also increased the odds of complete infant screening in univariate analysis (OR, 1.8; 95% CI, 1.1-2.8), but not in the adjusted model (aOR, 1.5; 95% CI, 0.9-2.5). No other factors significantly predicted completion of follow-up screening, although higher odds were observed with maternal HCV viremia (aOR, 1.3; 95% CI, 0.9-2.1), tobacco use (aOR, 1.8 95% CI, 0.9-3.6), and female infant sex (aOR, 1.5, 95% CI, 1.0-2.3).
Infants Diagnosed with HCV
Twelve children were diagnosed with chronic HCV. Only 5 were included in cascade outcomes because the others were either younger than 18 months at study end or excluded for having a younger sibling in the cohort. Ten infected infants (83%) were female and 11 (92%) were born full term. All mothers were receiving opioid agonist therapy at delivery-10 of the 12 (83%) were on methadone and 2 (17%) on buprenorphine. Of dyads in which the mother and infant had HCV genotypes, all infant genotypes matched their mothers': 4 dyads with genotype 1 and 2 with genotype 3 infection. All women who transmitted HCV infection to their infants were seropositive, but one had negative RNA testing early in pregnancy and no further testing during the study period (data not shown).
Discussion
Our analysis demonstrates that even a prenatal care program specifically serving women with substance use disorders and therefore at high-risk for HCV infection, assessed most, but not all, women for HCV. This finding demonstrates areas for improvement in the evaluation of viremia, linkage to care, and infant follow-up. Ultimately, 41% of women identified as HCV viremic were ever linked to HCV care and 45%-69% of HCVexposed infants had complete diagnostic testing for HCV transmission. The National Academies of Sciences, Engineering and Medicine concluded that HCV can be eliminated as a public health threat and laid out goals for reaching elimination in the US by 2030. 13 Achieving these goals requires efforts to identify and link patients with HCV infection to care, especially those under 40 years old, who are most likely to transmit. 1 Obstetric care provides a prime opportunity to identify womenand infants-at risk for HCV to test and link to care. Although linkage programs would provide economic value and likely be cost effective, establishing adequate wraparound services to The odds of completing follow-up screening for HCV (as defined in methods) for infants who were at least 18 months of age at study end and born to an HCV-seropositive mother. Boldface text indicates statistical significance. *Multivariable analysis adjusted for infant sex, distance from medical center, maternal HIV, presence of a psychiatric diagnosis, tobacco use, opioid agonist therapy, HCV viremia, and delivery date. †Data listed as n (%) indicating row percentages of infants with a given variable (of those with full data for that variable) who did or did not complete follow-up screening. Data were missing for more than 20 infants (5%) for the variables foster care (158 missing), maternal psychiatric diagnosis (34), HIV (32), infant sex (29), and smoking (23) . ‡Indicates miles from BMC by zip code centroid (8 miles is the approximate edge of the subway system). §Infant discharged to foster care at birth hospitalization discharge. ¶Illicit or unprescribed drug use within 30 days of delivery by urine toxicology screens. **Gestational age of less than 37 weeks at birth.
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bridge HCV-infected women and their infants to care and treatment remains a major challenge. 14 We found that women who delivered in more recent years had greater linkage to HCV care. This trend may reflect motivation for treatment in the new era of effective and tolerable antivirals with greater than 90% cure rates. However, prospective studies in this prenatal clinic may also contribute to increased testing and linkage, demonstrating a potential confounder but also a model of collaboration to improve the HCV care cascade.
Infants of women engaged in longitudinal chronic care for HIV and methadone maintenance therapy had higher univariate odds of completing infant screening. A smaller sample size, especially among HIV coinfected women, and a correlation between variables limited our ability to observe statistical significance in the multivariable analysis and created large CIs; however, effect sizes were large. These factors were not associated with women linking to their own HCV care. Perhaps not surprising, this finding provides insight into the effective design of programs intended to improve infant follow-up. Combining infant programs with chronic care for women could maximize infant HCV follow-up and provide needed services to women.
Infant HCV screening guidelines differ in recommendations to obtain HCV RNA testing. [9] [10] [11] [12] Infants with complete screening in this study include those with 2 negative HCV RNA tests before 18 months of age. If a guideline recommending only anti-HCV testing had been used by our institution, and some of these infants were lost to follow-up before completing the 18-month anti-HCV, our screening rate could have been lower. Nearly two-thirds of infants completed at least 1 HCV diagnostic test, suggesting a single-step algorithm that does not require sequential testing could improve infant diagnosis. The usefulness of obtaining a second RNA after an initial negative RNA performed at older than 2 months of age is uncertain and its added value should be further assessed. Likewise, many infants lose maternal anti-HCV before 18 months and an earlier recommended age to test could minimize the risk of loss to follow-up and better capture and diagnose infants. 15 Our imputation assumes maternal anti-HCV loss exactly at the midpoint between last positive and first negative anti-HCV, and a large prospective study testing anti-HCV at varying intervals would be required.
RESPECT is a unique multidisciplinary prenatal care program, and the pediatric infectious diseases program at BMC has dedicated nursing staff regularly following missed visits with several attempts to reschedule, and this factor limits generalizability to other centers. However, our finding of low linkage to care for women is consistent with findings in comparable programs in New Mexico and Pittsburgh. 16, 17 We expect new diagnoses of HCV in community-based general obstetrics practices, without the referral infrastructure of RESPECT, will pose even greater challenges. Lower infant screening rates predicted by public health reporting data in previous studies support this concern.
18-21 Delgado-Borrego et al compared the expected population prevalence of HCV with positive HCV laboratory data reported in children and found that only 11.7% of predicted pediatric HCV cases were ascertained in Florida and 4.9% across the country in 2009. 18 More recently, HCV diagnoses reported to public health departments matched with birth certificate data demonstrated only 16% of expected exposed infants had any HCV testing by 20 months of age in a Philadelphia study, and 34% completed appropriate testing in the Wisconsin Medicaid population. 19, 20 Finally, a large singlecenter study in Pittsburgh also demonstrated only a 30% screening rate for perinatal HCV, even in infants followed for primary care within their hospital system. 22 An important limitation of our data is that only testing and visits that occurred at BMC were captured. To the extent women and infants followed at alternative sites, we underestimate HCV screening, diagnoses, and linkage. However, even with the more conservative estimate including infants likely tested elsewhere by chart review analysis, only 69% completed HCV screening. Although more optimistic than previously reported rates, this represents 31% of HCV vertical transmission missed.
Foster care may alter the perinatal HCV screening cascade. Lack of medical history disclosure to foster parents poses potential for greater loss to follow-up. However, demographic differences and formal guidance for medical care of children in foster care could increase screening in this population. 23 We attempted to adjust for this, but foster care is not welldocumented in the EHR, which limited our ability to analyze this variable. Prospective studies could better delineate this association.
In addition, we used HCV genotype as a proxy for linkage to care. Genotype has been used by other studies to measure HCV linkage and is known to have good sensitivity and specificity as a marker for entering HCV care. 8, 16, 24 Using visit data can be misleading, because many provider types could offer HCV treatment, and not all visits to these providers are necessarily a visit focused on HCV.
Finally, we analyzed only the most recent pregnancy for each woman, which limited the sample size for infant analyses and ability to compare differences in linkage between initial and subsequent pregnancies. We did so to avoid double counting women in the cascade and multivariable analyses. It is unclear if multiple births over time would affect linkage to HCV care, which requires further exploration in the future.
As we implement strategies to eliminate HCV as a public health threat, we must be mindful of the increasing number of HCV infections among US women of reproductive age. Strategies to effectively screen and link women and their exposed infants to HCV care and treatment are essential, especially with direct acting antivirals now approved by the US Food and Drug Administration in children 12-17 years of age and being studied in those as young as age 3. 22 Our analysis characterizes the HCV care cascade among women in a high-risk prenatal population along with their exposed infants. We demonstrated a highyield venue for identifying and linking HCV-infected women to care and highlighted missed opportunities at each stage in the cascade to cure. Further research should address these gaps to improve progression through the HCV care cascade to achieve elimination goals. ■ Kaplan-Meier survival curve of time to maternal anti-HCV clearance for all 163 infants who ever had an initial positive anti-HCV followed by a negative antibody at a later time point. Imputed age in months at antibody clearance is calculated from the midpoint between age at last positive anti-HCV and first negative anti-HCV testing.
